The exact health benefits of administering the second dose of the Pfizer-BioNTech vaccine after six weeks, instead of the recommended three weeks, are currently being investigated.
One dose of this vaccine reduces the risk of hospitalisation or death for people over the age of 80 by 75%, according to new data released by the British health service Public Health England (PHE).
However, President of the European Commission Ursula von der Leyen has branded the British strategy, which postpones the second dose by up to 12 weeks, as “risky.”
Under the possible revision of the strategy in Belgium, an accelerated roll-out of the first dose in the second phase of the vaccination campaign, involving the low-risk general population, is also being discussed, De Standaard reports.
This means all available doses would be used to administer the first shots, meaning no second vaccine doses would have to be reserved to be given to those who already received one jab.
Altering the tactic in this way would also allow young adults to receive their first jab much sooner than previously expected.